Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288431 | 0.90 | — | — | |
| SCHEMBL14335319 | 0.89 | GABRR1 (0.50) | ALDH1A1KDM4ELMNATSHRGLRA1 | |
| SCHEMBL5664524 | 0.89 | KDM4E (0.58) | ALDH1A1KDM4ELMNATSHRGLRA1 | |
| SCHEMBL1537202 | 0.88 | ALDH1A1 (0.43) | ALDH1A1KDM4ELMNATSHRGLRA1 | |
| SCHEMBL15658062 | 0.88 | ALDH1A1 (0.43) | ALDH1A1KDM4ELMNATSHRGLRA1 | |
| Ammonia Solution, Strong SCHEMBL28253754 | 0.87 | GABRR1 (0.48) | ALDH1A1KDM4ELMNATSHRGLRA1 | |
| SCHEMBL28067630 | 0.87 | TSHR (0.62) | ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL10794891 | 0.87 | GLRA1 (0.41) | ALDH1A1KDM4ELMNAGLRA1SLC6A9 | |
| SCHEMBL6258848 | 0.87 | GLRA1 (0.41) | ALDH1A1KDM4ELMNAGLRA1SLC6A9 | |
| SCHEMBL6753492 | 0.87 | GLRA1 (0.41) | ALDH1A1KDM4ELMNAGLRA1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093814-A1 | Fusion Proteins Comprising Canine FC Portions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | claimed |
| EP-2413969-A2 | FUSION PROTEINS COMPRISING CANINE FC PORTIONS | Boehringer Ingelheim International GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| WO-2010117760-A2 | FUSION PROTEINS COMPRISING CANINE FC PORTIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| EP-2162464-A1 | NATRIURETIC FUSION PROTEINS | Boehringer Ingelheim International GmbH (DE) | 2010-03-17 | — | — | EP | claimed |
| WO-2008154226-A1 | NATRIURETIC FUSION PROTEINS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | claimed |
| US-20260027206-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260027204-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230321234-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230263887-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-11633476-B2 | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | MERCK SHARP & DOHME LLC (US) | 2023-04-25 | — | — | US | disclosed |
| CN-113563493-B | Hydrophobic polysaccharide and preparation method and application thereof | 蚌埠医学院 | 2022-06-24 | — | — | CN | disclosed |
| CN-113563493-A | Hydrophobic polysaccharide and preparation method and application thereof | 蚌埠医学院 | 2021-10-29 | — | — | CN | disclosed |
| WO-2008154226-A1 | NATRIURETIC FUSION PROTEINS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| CN-1612896-A | Peptide Purification by Metal Ion Affinity Chromatography | NOVO NORDISK AS (DK) | 2005-05-04 | — | — | CN | disclosed |
| EP-0815114-B1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | UNIV DUKE (US) | 2004-05-12 | — | — | EP | disclosed |
| US-5908926-A | 5'to 3' nucleic acid synthesis using 3'-photoremovable protecting group | DUKE UNIVERSITY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0815114-A4 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | UNIV DUKE (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0815114-A1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | DUKE UNIVERSITY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996033953-A1 | STAIN CORROSION AND SCALE INHIBITORS | ALBRIGHT & WILSON UK LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996028457-A1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | DUKE UNIVERSITY (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027206-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | PDCD1, CD274, PDCD10 | ALDH1A1 4339/4885KDM4E 2125/4885LMNA 4362/4885 |
| US-20120093814-A1 | Fusion Proteins Comprising Canine FC Portions | FCGRT, FCGR3B, FCGR2A | ALDH1A1 4485/4885KDM4E 4121/4885LMNA 4568/4885 |
| US-20260027204-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | PDCD1, CD274, PDCD10 | ALDH1A1 4341/4885KDM4E 2129/4885LMNA 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.